{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/fa3ecf27-4910-41db-9127-4174e03e78df/aadb2c77-a935-48cf-8215-7b872522794e?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"First human trial of engineered T cells","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61b9b47d42e8568ca498578e/61b9b4d59d2148001360f25d.png?height=200","description":"<p>Senior Editor Markus Elsner talks to Alex Marson of UCSF about the significance of a <em>Science</em><strong><em> </em></strong>paper describing the phase 1 clinical trial of CRISPR-engineered T cells. The work was carried out by Carl June and Edward Stadtmauer from UPenn. Read the paper <a href=\"https://science.sciencemag.org/content/367/6481/eaba7365\" rel=\"noopener noreferrer\" target=\"_blank\">here</a>.</p>","author_name":"Nature Biotechnology"}